Thein uenzavaccine eldhasbeenconstantlyevolvingtoimprovethespeed,scalability,and exibilityofmanufacturing,andto
improvethebreadthandlongevityoftheprotectiveimmuneresponseacrossagegroups,givingrisetoanarrayofnextgeneration
vaccinesindevelopment.Amongthese,therecombinantinfluenzavaccinetetravalent(RIV4),usingabaculovirusexpressionvector
systemtoexpressrecombinanthaemagglutinin(rHA)ininsectcells,istheonlyonetohavereachedthemarketandhasbeen
studiedextensively.WedescribehowtheuniquestructuralfeaturesofrHAinRIV4improveprotectiveimmuneresponsescompared